Targeting NEDD4-1, particularly by using its direct inhibitor IC3, significantly reversed PTEN degradation, inhibited AKT/NRF2/HO-1 signaling, and increased ROS level and cell death in GBM cells. The gene discussed is PTEN; the disease is glioblastoma.